|
1. BIOLOGIE
|
|
|
Oxygen-Starved Tumor Cells Have Survival Advantage That Promotes Cancer Spread [Johns Hopkins]
|
|
|
|
|
|
The experiments mapping the “fate” of the cells in two- and three-dimensional lab-created tissue systems and in live animals specifically showed that cells from a primary cancer exposed to low oxygen levels, or hypoxia, have a four times greater probability of becoming viable circulating tumor cells—and likely spreading to distant tissues—than those under normal oxygen conditions.
|
|
|
|
|
|
|
1.1 BIOLOGIE - GÉNOME
|
|
|
Double trouble for cancer gene [Science]
|
|
|
|
|
|
The consequences of harboring double PIK3CA mutations on the same allele are far-reaching. Vasan et al. show that double PIK3CA mutations lead to significantly increased PI3K activity and downstream pathway activation when compared with those of single-hotspot mutations. This results in enhanced tumor growth in vivo.
|
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
|
Juul Ends E-Cigarette Sales of Mint-Flavored Pods [NY Times]
|
|
|
|
|
|
The company’s decision also followed the release earlier this week of two major surveys showing another year-over-year spike in teenage vaping of e-cigarettes, and the rising popularity of mint-flavored nicotine pods as other youth-friendly flavors like unicorn milk were pulled from retail shelves.
|
|
|
|
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
4.5 DÉP., DIAG. & PRONO. - COLORECTAL
|
|
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
Cancer Cells Increase DNA Mutations to Evade Treatment [The Scientist]
|
|
|
|
|
|
In response to antibiotic treatment, bacteria improve their odds of survival by increasing the rate of mutations in their genomes, giving them more chances to become resistant. The tactic isn’t limited to microbes. In a study published in Science, researchers have shown that colorectal cancer cells likewise increase their mutation rate to avoid death by a targeted therapy.
|
|
|
|
|
|
|
|
Learning to stop cancer at its roots [Baylor College of Medicine]
|
|
|
|
|
|
“The results of the drug discontinuation trials suggest that a cure may not be possible with tyrosine kinase inhibitors alone. We think that new breakthroughs in chronic myeloid leukemia therapy may emerge from the identification of novel mechanisms of leukemia stem cell self-renewal and the development of drugs that specifically target these mechanisms.”
|
|
|
|
|
|
|
5.12 IMMUNOTHÉRAPIES
|
|
|
|
5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH
|
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
5.8 ASH
|
|
|
Celgene posts pivotal CAR-T data ahead of FDA filing [Fierce Biotech]
|
|
|
|
|
|
The response rates are around 20 percentage points higher than those on the Kymriah label and one or two percentage points above the results achieved by Yescarta. As the three drugs were studied in different trials, factors other than their efficacy may account for the differences.
|
|
|
|
|
|
|
|
5.8.1 ASH - COMMUNIQUÉS
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
|
|
|
|
|
6.7.2 APPLIS
|
|
|